TNF Alpha in Refractory Asthma
|ClinicalTrials.gov Identifier: NCT00276029|
Recruitment Status : Completed
First Posted : January 12, 2006
Last Update Posted : May 4, 2006
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: Etanercept||Not Applicable|
Although steroid dependent asthma represents a small population of patients with asthma, they consume a disproportionately large amount of the health resource burden attributed to asthma. Treatment options in this group are extremely limited; the development of effective treatments for this group of patients should be a priority, not only for increasing individual patient quality of life but for long term reduction of health spending.
This randomised, double blind, placebo controlled, cross over trial will investigate the efficacy of a soluble TNF receptor, etanercept, in severe, steroid dependant asthma.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||10 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||The Efficacy of a Soluble Ligand Binding Tumour Necrosis Factor Receptor, Etanercept, in Severe, Steroid Dependant Asthma: a Randomised Controlled Study|
|Study Start Date :||December 2003|
|Study Completion Date :||September 2004|
- Methacholine PC20
- Juniper asthma quality of life
- Net change in post-bronchodilator FEV1
- symptom visual analogue score
- exhaled nitric oxide concentration
- computed alveolar nitric oxide concentration
- sputum differential inflammatory cell counts
- sputum supernatant mediator concentration.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00276029
|Institute for Lung Health|
|Leicester, Leicestershire, United Kingdom, LE3 9QP|
|Principal Investigator:||Michael A Berry, MB, ChB||Institute for Lung Health|